Skip to main content

Research Repository

Advanced Search

All Outputs (1)

Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease (2008)
Journal Article
Wakil, A., Rigby, A. S., Clark, A. L., Kallvikbacka-Bennett, A., & Atkin, S. L. (2008). Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease. European journal of endocrinology, 159(4), R11-R14. https://doi.org/10.1530/eje-08-0365

OBJECTIVE: Recent trials suggest that using ergot-derived dopamine agonists such as cabergoline in the treatment of Parkinson's disease is associated with an increased risk of valvular heart disease. However, the dose of cabergoline used to treat hyp... Read More about Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease.